Scholar Rock (NASDAQ:SRRK) Price Target Raised to $70.00 at BMO Capital Markets

Scholar Rock (NASDAQ:SRRK) had its price target lifted by BMO Capital Markets from $50.00 to $70.00 in a report released on Wednesday morning,Benzinga reports. BMO Capital Markets currently has an outperform rating on the stock.

A number of other research analysts have also weighed in on SRRK. Piper Sandler boosted their target price on Scholar Rock from $51.00 to $58.00 and gave the stock an “overweight” rating in a report on Wednesday. JPMorgan Chase & Co. lifted their price objective on shares of Scholar Rock from $46.00 to $47.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 18th. HC Wainwright reissued a “buy” rating and issued a $58.00 price objective on shares of Scholar Rock in a research report on Tuesday. Cantor Fitzgerald restated an “overweight” rating on shares of Scholar Rock in a research note on Thursday, December 11th. Finally, Truist Financial upped their price target on shares of Scholar Rock from $44.00 to $55.00 and gave the company a “buy” rating in a research note on Tuesday. Four analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Scholar Rock presently has an average rating of “Buy” and a consensus price target of $54.14.

Scholar Rock Trading Up 7.0%

Shares of NASDAQ:SRRK opened at $47.43 on Wednesday. Scholar Rock has a 52-week low of $22.71 and a 52-week high of $49.82. The company has a market capitalization of $4.84 billion, a P/E ratio of -13.83 and a beta of 0.70. The company has a 50-day simple moving average of $45.32 and a 200 day simple moving average of $39.14. The company has a debt-to-equity ratio of 0.41, a quick ratio of 6.30 and a current ratio of 6.30.

Scholar Rock (NASDAQ:SRRK) last announced its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.76) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.86) by $0.10. During the same period last year, the company posted ($0.64) EPS. Sell-side analysts forecast that Scholar Rock will post -2.42 earnings per share for the current year.

Insider Buying and Selling at Scholar Rock

In other Scholar Rock news, insider Mo Qatanani sold 8,484 shares of the business’s stock in a transaction dated Monday, February 23rd. The shares were sold at an average price of $47.07, for a total value of $399,341.88. Following the completion of the sale, the insider owned 98,445 shares of the company’s stock, valued at $4,633,806.15. The trade was a 7.93% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, General Counsel Junlin Ho sold 9,580 shares of the stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $46.53, for a total transaction of $445,757.40. Following the transaction, the general counsel owned 241,545 shares in the company, valued at approximately $11,239,088.85. The trade was a 3.81% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 208,470 shares of company stock worth $9,201,778. Insiders own 13.30% of the company’s stock.

Institutional Investors Weigh In On Scholar Rock

Large investors have recently added to or reduced their stakes in the stock. Moody Aldrich Partners LLC increased its position in shares of Scholar Rock by 53.5% in the third quarter. Moody Aldrich Partners LLC now owns 101,742 shares of the company’s stock worth $3,789,000 after purchasing an additional 35,481 shares during the period. Norges Bank acquired a new stake in Scholar Rock during the second quarter worth about $41,628,000. Voya Investment Management LLC increased its holdings in Scholar Rock by 18.1% in the 3rd quarter. Voya Investment Management LLC now owns 443,155 shares of the company’s stock valued at $16,503,000 after buying an additional 67,839 shares during the period. Nan Fung Trinity HK Ltd. bought a new position in Scholar Rock in the 3rd quarter valued at about $1,402,000. Finally, Ensign Peak Advisors Inc raised its position in shares of Scholar Rock by 78.8% in the 2nd quarter. Ensign Peak Advisors Inc now owns 600,639 shares of the company’s stock valued at $21,275,000 after buying an additional 264,693 shares in the last quarter. Institutional investors and hedge funds own 91.08% of the company’s stock.

Key Scholar Rock News

Here are the key news stories impacting Scholar Rock this week:

• Positive Sentiment: BMO Capital Markets raised its price target from $50 to $70 and kept an “outperform” rating (~47.6% upside vs. the current price). BMO Raises PT to $70
• Positive Sentiment: Citigroup raised its target to $58 and maintained a “buy” rating (~22% upside). Citigroup Raises PT to $58
• Positive Sentiment: Piper Sandler raised its target to $58 and kept an “overweight” rating (similar ~22% upside). Piper Sandler PT Raise Street Insider
• Positive Sentiment: HC Wainwright reaffirmed a “buy” and a $58 target. HC Wainwright Reaffirmation TickerReport
• Positive Sentiment: Q4 results narrowly beat expectations — reported EPS (net loss) was ($0.76) vs. consensus (~$0.86), which analysts viewed positively relative to estimates. Earnings Release / Summary
• Neutral Sentiment: Full earnings and Q&A transcripts are now available (multiple outlets posted call transcripts), useful for digging into pipeline updates and management tone. Seeking Alpha Transcript InsiderMonkey Transcript
• Negative Sentiment: Despite the beat, the corrected press release clarifies net loss per share was $0.76 for Q4 vs. $0.61 a year earlier — an increase in the loss year‑over‑year, underscoring ongoing unprofitability. BusinessWire Correction

Scholar Rock Company Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).